OBJECTIVE: To compare the outcome of patients diagnosed with HIV infection and diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP in the cART era with that of a HIV-negative control group. METHODS: From 2003 to 2011, 305 patients (97 HIV-positive) were diagnosed with DLBCL and treated with R-CHOP. Clinical features were compared using chi-square or Fisher's exact test. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Multivariate analysis was performed using the Cox regression proportional hazards model. RESULTS: HIV-positive patients had more B symptoms and extranodal sites of disease at diagnosis, but the proportion of patients with high-intermediate/high-risk disease according to the international prognostic index (IPI) was similar between groups. Response rate was 73%, both for patients with and without HIV infection. After a median follow-up of 48 months, 30 patients relapsed after achieving a complete remission, including four HIV-positive patients. Ninety-six patients have died (19 HIV-positive), 73 of them due to DLBCL. Three patients (one HIV-positive) died due to treatment toxicity. Patients with HIV infection had a significantly longer disease-free survival (DFS) (5-year: 94 vs. 77%; P = 0.03) and overall survival (OS) (78 and 64% for HIV-positive and HIV-negative patients, respectively; P = 0.03). These results were confirmed on multivariate analysis when controlled for other potential prognostic confounders. CONCLUSION: HIV-positive patients diagnosed with DLBCL in the cART era have an excellent outcome when treated with standard immunochemotherapy. Therefore, the choice of chemotherapy in patients with lymphoma should not be influenced by HIV status.
OBJECTIVE: To compare the outcome of patients diagnosed with HIV infection and diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP in the cART era with that of a HIV-negative control group. METHODS: From 2003 to 2011, 305 patients (97 HIV-positive) were diagnosed with DLBCL and treated with R-CHOP. Clinical features were compared using chi-square or Fisher's exact test. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Multivariate analysis was performed using the Cox regression proportional hazards model. RESULTS: HIV-positive patients had more B symptoms and extranodal sites of disease at diagnosis, but the proportion of patients with high-intermediate/high-risk disease according to the international prognostic index (IPI) was similar between groups. Response rate was 73%, both for patients with and without HIV infection. After a median follow-up of 48 months, 30 patients relapsed after achieving a complete remission, including four HIV-positive patients. Ninety-six patients have died (19 HIV-positive), 73 of them due to DLBCL. Three patients (one HIV-positive) died due to treatment toxicity. Patients with HIV infection had a significantly longer disease-free survival (DFS) (5-year: 94 vs. 77%; P = 0.03) and overall survival (OS) (78 and 64% for HIV-positive and HIV-negative patients, respectively; P = 0.03). These results were confirmed on multivariate analysis when controlled for other potential prognostic confounders. CONCLUSION: HIV-positive patients diagnosed with DLBCL in the cART era have an excellent outcome when treated with standard immunochemotherapy. Therefore, the choice of chemotherapy in patients with lymphoma should not be influenced by HIV status.
Authors: S K Barta; M S Samuel; X Xue; D Wang; J Y Lee; N Mounier; J-M Ribera; M Spina; U Tirelli; R Weiss; L Galicier; F Boue; R F Little; K Dunleavy; W H Wilson; C Wyen; S C Remick; L D Kaplan; L Ratner; A Noy; J A Sparano Journal: Ann Oncol Date: 2015-01-28 Impact factor: 32.976
Authors: R Ramaswami; A Dalla Pria; K Parker; S McCann; E J Kanfer; M Nelson; M Bower Journal: Bone Marrow Transplant Date: 2016-09-05 Impact factor: 5.483
Authors: Matthew S Painschab; Edwards Kasonkanji; Takondwa Zuze; Bongani Kaimila; Tamiwe Tomoka; Richard Nyasosela; Ruth Nyirenda; Bal M Dhungel; Maurice Mulenga; Maria Chikasema; Blessings Tewete; Asekanadziwa Mtangwanika; Sarah Chiyoyola; Wilberforce Mhango; Fred Chimzimu; Coxcilly Kampani; Robert Krysiak; Thomas C Shea; Nathan D Montgomery; Yuri Fedoriw; Satish Gopal Journal: Br J Haematol Date: 2018-11-18 Impact factor: 6.998
Authors: Keri L Calkins; Geetanjali Chander; Corinne E Joshu; Kala Visvanathan; Anthony T Fojo; Catherine R Lesko; Richard D Moore; Bryan Lau Journal: JAMA Oncol Date: 2020-02-01 Impact factor: 31.777